Clinical Trial

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Study acronym: ADVICE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-07; most recent amendment 2026-03-15.
Status change: Not Yet Recruiting → Recruiting 2025-11-20
Trial Details
NCT Number NCT06926075
Lead Sponsor Filamon LTD
Conditions Prostate Cancers, Breast Cancer, Lung Cancers, Ovarian Cancer, Glioblastoma Multiforme (GBM), Pancreas Cancer, Skin Cancer
Enrollment 80 participants
Start Date 2025-11-07
Primary Completion 2027-10-26 (estimated)
Study Completion 2027-10-26 (estimated)
Updated on ClinicalTrials.gov 2026-03-17